Certificate of Analysis (COA)
View the laboratory certificate for this product
[ View COA ]
Body Pharma R3t@trutide 64mg Multi-Dose Injection Pen
R 5,200.00 R 4,480.00
Retatrutide 64mg Research Pen is a peptide research product featuring retatrutide (LY3437943), an investigational triple receptor agonist that activates the GIP, GLP-1, and glucagon receptors. Retatrutide is currently being evaluated in clinical research programs investigating metabolic health, obesity, type 2 diabetes, and related cardiometabolic conditions.
This 64mg pre-filled research pen is designed for laboratory and research-focused applications, providing a convenient pen-format presentation for researchers working with retatrutide. The compound remains investigational and is not currently FDA-approved for public use.
Retatrutide 64mg research pen; LY3437943; GIP, GLP-1 and glucagon triple receptor agonist; pre-filled pen format; designed for laboratory and peptide research applications; 64mg labelled research presentation.
Research reference: Retatrutide (LY3437943), an investigational GIP/GLP-1/glucagon triple receptor agonist. Published research and ongoing clinical programs are evaluating its pharmacology and potential applications in metabolic research. Laboratory use and research reference only. Not approved by the FDA for public use. No dosing or administration instructions are provided.
What is Retatrutide? Retatrutide, also known as LY3437943, is an investigational GIP, GLP-1 and glucagon receptor agonist. Is Retatrutide FDA approved? No, it remains investigational. What is Retatrutide studied for? Research programs are evaluating obesity, type 2 diabetes and other metabolic conditions. What does 64mg refer to? It refers to the labelled quantity of research material in this product presentation. Is this a dosing product? This listing is intended for laboratory and research reference purposes and does not provide treatment or dosing guidance.
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that activates the GIP, GLP-1 and glucagon receptors. It is being evaluated in clinical research programs examining obesity, type 2 diabetes and other cardiometabolic conditions. Current clinical research includes multiple Phase 3 programs.
